Momentum Biotechnologies, a contract research organization (CRO) specializing in mass spectrometry-based drug discovery, has acquired OmicScouts GmbH, a Munich-based CRO and leader in the field of mass spectrometry-based proteomics. Moving forward, the company will operate as OmicScouts, a Momentum Biotechnologies Company.

With this transaction, Momentum gains access to a portfolio of well-validated proteomic assays that enhance and extend its existing service offerings, enabling clients to seamlessly progress from high-throughput screening into cell-based assays, as well as to discover new targets and biomarkers. The acquisition also enables immediate geographic expansion into the European market, further realizing Momentum’s strategic commitment to providing scientific services to biopharmaceutical innovators worldwide.

“Our clients have long requested our help triaging and further interrogating the hits we uncover through high-throughput screens. With the addition of OmicScouts’ leading chemoproteomic capabilities, we are now able to take projects beyond hit identification to interrogate target engagement, selectivity/specificity, and global drug response, effectively closing the existing gap between biochemical hit triage and downstream cell-based and preclinical assays,” said Can Ozbal, Ph.D., founder and CEO of Momentum Biotechnologies. “We are excited about this opportunity to expand our service capabilities while maintaining our mutual commitments to customer satisfaction, scientific rigor, and ongoing technological innovation.”

OmicScouts’ co-founder and CEO Hannes Hahne, Ph.D. will transition into a new role as President and member of Momentum’s global executive leadership team following the integration.

Furthermore, two of OmicScouts’ co-founders and scientific advisers, Mathias Wilhelm, Ph.D., and Bernhard Kuster, Ph.D., will join Momentum’s Scientific Advisory Board, where they will serve as resources for the combined team.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.